期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗结核新靶点及相关药物的研究进展 被引量：4

Advances in new anti-tuberculosis targets and related drugs
暂未订购
导出
摘要 肺结核是一种由结核分枝杆菌(Mycobacterium tuberculosis)感染引起的,严重威胁人类健康的传染病。近年来,多药耐药和广泛耐药型结核杆菌的出现给该疾病的控制带来了巨大挑战,在新趋势下,迫切需要作用于新靶点的抗结核药物诞生。本文从结核杆菌细胞生长涉及的必需生物过程、结核杆菌致病和耐药机制3个角度出发,系统综述了抗结核领域新靶点及相关药物的研究进展。 Tuberculosis（TB） is a major global health threat which is caused by Mycobacterium tuberculosis.The emergence of multidrug resistant（MDR） and extremely drug-resistant（XDR） TB poses a vital challenge to the control of this disease,and thus there is an urgent need for new drugs with novel targets.This review describes advances in new targets of anti-tuberculosis which are involved in the essential growth processes,mechanisms of pathogenic resistance of Mycobacterium tuberculosis.The development of related drugs for those targets is also summerized.
作者 汪静 张惠斌 周金培 李清
机构地区 中国药科大学药物化学教研室
出处 《中国药科大学学报》 CAS CSCD 北大核心 2012年第1期1-8,共8页 Journal of China Pharmaceutical University
基金 国家自然科学基金资助项目(No.30973638) 江苏省产学研联合创新资金资助项目(No.BY2011158)~~
关键词 结核分枝杆菌 抗结核 靶点 耐药 研究进展 Mycobacterium tuberculosis anti-tuberculosis target drug resistance advances
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献58

  • 1World Health Organization. Tuberculosis MDR-TB & XDR-TB 2011 progress report[ EB/OL]. (2011-03-23) [2011-11-25 ]. http ://www. who. int/tb/challenges/mdr/factsheet _ mdr_ progress_march2011, pdf.
  • 2王天才,周金培,张惠斌.抗结核药物的研究进展[J].中国药科大学学报,2010,41(4):299-305. 被引量：8
  • 3Boshoff HIM, Barry CE. Tuberculosis-metabolism and respiration in the absence of growth[J]. Nat Rev Microbiol,2005,3( 1 ) :70 - 80.
  • 4Munoz-Elias EJ, McKinney JD. Carbon metabolism of intracellular bacteria[ J]. Cell Microbiol,2006,8( 1 ) :10 -22.
  • 5Munoz-Elias EJ, McKinney JD. Mycobacterium tuberculosis isocitrate lyase 1 and 2 are jointly required for in vitro growth and virulence[ J]. Nat Med,2005,11(6) :638 -644.
  • 6Gould TA, Langemheen HVD, Munoz-Elias E J, et al. Dual role of isocitrate lyase 1 in the glyoxylate and methylcitrate cycles in Mycobacterium tuberculosis [ J ]. Mol Microbiol,2006 ,61 (4) : 940 - 947.
  • 7Sriram D,Yogeeswari P, Senthilkumar P, et al. Novel pthalazinyl derivatives : synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis isocitrate lyase enzyme [ J ]. Med Chem,2009,5(5 ) :422 -433.
  • 8Parish T, Stoker NG. The common aromatic amino acid biosynthesis pathway is essential in Mycobacterium tuberculosis [ J ]. Microbiology, 2002,148 ( 10 ) : 3 069 - 3 077.
  • 9Segura-Cabrera A, Rodriguez-Perez MA. Structure-based prediction of Mycobacterium tuberculosis shikimate kinase inhibitors by high-throughput virtual screening [ J ]. Bioorg Med Chem Lett, 2008,18(11) :3 152 -3 157.
  • 10Kumar M, Verma S, Sharma S, et al. Structure-based in silico design of a high-affinity dipeptide inhibitor for novel protein drug target shikimate kinase of Mycobacterium tuberculosis [ J ]. Chem Biol Drug Des ,2010,76( 3 ) :277 - 284.

二级参考文献35

  • 1Kim P, Kang S, Boshoff HI, et al. Structure-activity relation-ships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activlty relationships[ J]. J Med Chem,2009,52(5) :1 329 - 1 344.
  • 2Sasaki H,Haraguchi Y,Itotani M,et al. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3- dihydro-imidazo[ 2,1-b ] oxazoles [ J ]. J Med Chem, 2006,49 (26) :7 785 -7 860.
  • 3Matsumoto M, Hashizumel H,Tomishigel T,et al. OPC-67683 ,a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice[J]. PLoS Med,2006,3(11) :2 131 -2 144.
  • 4Koul A, Dendouga N, Vergauwen K, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase [ J ]. Nat Chem Biol, 2007,3 (6) : 323 - 324.
  • 5de Jonge MR, Koymans LH, Guillemont JE,et al. A computational model of the inhibition of Myeobacteriurn tuberculosis ATPase by a new drug candidate R207910 [ J ]. Proteins,2007,67 (4) : 971 - 980.
  • 6Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ,et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue [ J ]. Antimicrob Agents Chemother ,2009 ,53 ( 3 ) : 1 290 - 1 292.
  • 7Andries K, Verhasseh P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis [J]. Science,2005,307(5 707) :223 - 227.
  • 8Lenaerts A J, Hoff D, Aly S,et al. Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by R207910[J]. Antimicrob Agents Chemother, 2007,51 ( 9 ) : 3 338 - 3 345.
  • 9Veziris N,Ibrahim M, Lounis N,et al. Once-weekly R207910-containing regimen exceeds activity of thestandard daily regimen in murine tuberculosis [ J ]. Am J Respir Crit Care Med, 2009, 179(/) :75 -79.
  • 10Ibrahim M, Andries K, Lounis N, et al. Synergistic activity of R207910 combined with pyrazinamideagainst murine tuberculosis [ J ]. Antimicrob Agents Chemother,2007,51 (3) : 1 011 - 1 015.

共引文献7

同被引文献19

引证文献4

二级引证文献10

中国药科大学学报
2012年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部